MicroPort NeuroTech Limited (2172.HK) HKSE
9.39
-0.03(-0.32%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
9.39
-0.03(-0.32%)
Currency In HKD
Sector
Healthcare
Industry
Medical - Devices
Employees
527
First IPO Date
July 15, 2022
| Name | Title | Pay | Year Born |
| Zhiyong Xie | Chief Executive Officer, Executive Director & Chairman of MicroPort NeuroTech | 1.24M | 1976 |
| Yiqun Wang | Senior Vice President & Executive Director | 1.83M | 1965 |
| Siu Lam Yeung | Company Secretary | 0 | N/A |
| Zaoli Wu | Manager of Human Resources & Administration | 0 | 1983 |
| Lei Duan | Chief Marketing Officer and SVP of Sales & Promotion of Neurovascular Disease Treatment Solutions | 0 | 1982 |
| Zhuoping Hou | Senior Director of Finance | 0 | 1978 |
| Wangcai Liao | Chief Technology Officer | 0 | 1964 |
MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial arterial stent system to treat intracranial atherosclerotic disease; and Bridge, a rapamycin target eluting vertebral artery stent system to treat cerebral atherosclerotic stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.